Compare TransMedics Group Inc (TMDX) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard S&P 500 ETF — how do they compare? TransMedics Group Inc trades at $87.59 (market cap $3.10B), while Vanguard S&P 500 ETF trades at $709.62. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | VOO | |
|---|---|---|
Market Cap | $3.10B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $150.42 | $710.71 |
52-Week Low | $61.99 | $580.93 |
Enterprise Value | $3.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
VOO, the Vanguard S&P 500 ETF, trades at $710.19, down slightly by 0.06% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF is near its pivot point of $709, with immediate resistance at $711. Recent news highlights the S&P 500 at record highs, with JPMorgan raising its year-end target to 8,000, citing strong earnings and AI-driven growth, while some caution emerges from overbought signals and high valuations.
The outlook remains positive given institutional bullishness and AI tailwinds, but risks include market overvaluation, potential pullbacks from overbought conditions, and sensitivity to inflation data. Long-term investors may benefit from dollar-cost averaging, though short-term volatility warrants caution amid elevated sentiment and technical indicators signaling near-term exhaustion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
